CD274 and neoplasm: Of the existing biomarkers for gastric cancer immunotherapy, such as PD-L1 expression, MSI, tumor mutational burden (TMB), EBV status, liquid biopsy, and emerging multi-omics approaches, many have significantly improved the precision of predicting immunotherapy efficacy.